Digital Assets Report


Like this article?

Sign up to our free newsletter

Ruthenium Global Pharma Fund outperforms S&P500 by 25.96% in H1 2022

Related Topics

The Ruthenium Global Pharma Fund outperformed the S&P500 by 25.96% in the first half of 2022 with its YTD return reaching 5.46%.

The fund aims to generate long-term returns through a strategy focused on investments in the global pharmaceutical and biotechnology sectors. With the diversified portfolio of high-yielding structured products, the fund is one of the few showing positive results while markets are tumbling worldwide. 

Currently, there are 16 structured notes in the fund’s portfolio with an average maturity of 28 months and an average coupon rate of 22,90%. The Ruthenium Global Pharma Fund achieved a 12,38% compounded annual return in H1 2022 and a 1,10% average monthly return since its launch date in October 2020. The fund has been demonstrating consistently positive results since its first year of operations when it showed a performance of 16,1%. 

At the same time, the S&P 500 has posted its worst first half in more than 50 years, dropping over 20%. The Dow Jones Industrial Average fell by more than 15%, the most significant drop since 1962. The technology-focused Nasdaq Composite suffered losses close to 30%. The economy is on the verge of a recession, plagued by high inflation and rising interest rates.

The Ruthenium Global Pharma Fund is in the top 10 performing funds in Barclay Hedge Health Care/Biotech ranking. It also features in The Credit Suisse Hedge Fund Index.

Like this article? Sign up to our free newsletter

Most Popular

Further Reading